Roche and its subsidiary, Foundation Medicine Inc. (FMI), in collaboration with PT Kalbe Farma Tbk., through Kalgen Innolab, launched a CGP examination service with Next Generation Sequencing (NGS) technology. This new screening service can help determine an optimal therapy for cancer patients, according to a patient’s tumor genomic crisis. Two types of tests will be available for doctors to use on patients. FoundationOneCDx examination is indicated for all types of solid tumor cancer by analyzing DNA samples, while FoundationOneHeme is for patients with hematological disorders and sarcomas at all stages, by analyzing the patient’s DNA and RNA.
Read: HIV testing, bring it on!
The two tests can comprehensively detect the transport of more than 300 genes related to cancer growth. These mutations then become an indication of a patient’s compatibility with certain cancer therapy options, which can assist doctors and patients in determining the most appropriate therapy, based on their genome profile. Yuniar Linda, President Director of Kalgen Innolab, explained, “The FoundationOneCDx examination is a milestone in the history of our service, one which is expected to provide more benefits and superior quality of Indonesian health, while answering the challenges of the development of the world of biomolecular medicine, especially for the treatment of cancer patients.” (est)